https://orcid.org/0000-0001-7875-7386
References
- Fiscella RG, Green A, Patuszynski DH, Wilensky J. Medical therapy cost considerations for glaucoma. Am J Ophthalmol. 2003;136(1):18–25. doi:10.1016/s0002-9394(03)00102-812834665
- Kingman S. Glaucoma Is Second Leading Cause of Blindness Globally. World Health Organization; 2004.
- Foundation BF. Glaucoma: facts & figures. Bright Focus Foundation; 2017 Available from: http://www.brightfocus.org/glaucoma/article/glaucoma-facts-figures. Accessed 324, 2016.
- Glaucoma Research Society of Canada. Quick facts; 2018 Available from: https://www.glaucomaresearch.ca/about/about-glaucoma/. Accessed 531, 2018.
- Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262–267. doi:10.1136/bjo.2005.08122416488940
- MEDEC’s Ophthalmic Sector Committee. Economic benefits of treatment. MEDEC; 2018 Available from: http://www.medec.org/webfm_send/434. Accessed 321, 2018.
- Varma R, Lee PP, Goldberg I, Kotak S. An assessment of the health and economic burdens of glaucoma. Am J Ophthalmol. 2011;152(4):515–522. doi:10.1016/j.ajo.2011.06.00421961848
- Lee PP, Walt JG, Doyle JJ, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol. 2006;124(1):12. doi:10.1001/archopht.124.1.1216401779
- Health Canada. The safety and effectiveness of generic drugs; 2012 Available from: https://www.canada.ca/en/health-canada/services/healthy-living/your-health/medical-information/safety-effectiveness-generic-drugs.html. Accessed 321, 2018.
- Kahook MY, Fechtner RD, Katz LJ, Noecker RJ, Ammar DA. A comparison of active ingredients and preservatives between brand name and generic topical glaucoma medications using liquid chromatography-tandem mass spectrometry. Curr Eye Res. 2012;37:1–8.22029631
- Mammo ZN, Flanagan JG, James DF, Trope GE. Generic versus brand-name North American topical glaucoma drops. Can J Ophthalmol. 2012;47(1):55–61. doi:10.1016/j.jcjo.2011.12.00422333853
- Rylander NR, Vold SD. Cost analysis of glaucoma medications. Am J Ophthalmol. 2008;145(1):106–113. doi:10.1016/j.ajo.2007.08.04118154755
- Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997–2000. Ann Intern Med. 2005;142(11):891–897. doi:10.7326/0003-4819-142-11-200506070-0000615941695
- Schenker HI, Silver LH. Long-term intraocular pressure lowering efficacy and safety of timolol maleate gel-forming solution 0.5% compared with timoptic XE 0.5% in a 12-month study. Am J Ophthalmol. 2000;130(2):145–150. doi:10.1016/s0002-9394(00)00458-x11004287
- Gallardo MJ, Fiscella RG, Whitson JT. Generic Glaucoma Medications. Is It Safe to Switch? 2006.
- Stein JD, Shekhawat N, Talwar N, Balkrishnan R. Impact of the introduction of generic latanoprost on glaucoma medication adherence. Ophthalmology. 2015;122(4):738–747. doi:10.1016/j.ophtha.2014.11.02225680226
- Vold SD, Riggs WL, Jackimiec J. Cost analysis of glaucoma medications: a 3-year review. J Glaucoma. 2002;11(4):354–358.12169974
- Schlenker MB, Trope GE, Buys YM. Comparison of United States and Canadian glaucoma medication costs and price change from 2006 to 2013. J Ophthalmol. 2015;2015.
- Lee R, Hutnik CML. Projected cost comparison of selective laser trabeculoplasty versus glaucoma medication in the Ontario Health Insurance Plan. Can J Ophthalmol. 20;41(4):449–456. doi:10.1016/S0008-4182(06)80006-2
- Ontario Drug Benefit (ODB) Formulary. Drugs and Devices Division; 2018 Available from: http://www.health.gov.on.ca/en/pro/programs/drugs/odbf_mn.aspx. Accessed 119, 2018.
- Ministry of Health and Long-term Care O, Canada. Ontario drug benefit program: dispensing fees. Ministry of Health and Long-term Care; 2019 Available from: http://www.health.gov.on.ca/en/public/programs/drugs/programs/odb/opdp_dispensing_fees.aspx. Accessed 531, 2019.
- Iordanous Y, Kent JS, Hutnik CM, Malvankar-Mehta MS. Projected cost comparison of trabectome, iStent, and endoscopic cyclophotocoagulation versus glaucoma medication in the Ontario Health Insurance Plan. J Glaucoma. 2014;23(2):e112–8. doi:10.1097/IJG.0b013e31829d9bc7.
- Service Ontario. Ontario drug benefit act; 2018 Available from: http://www.e-laws.gov.on.ca/html/regs/english/elaws_regs_960201_e.htm. Accessed 318, 2018.
- Kim YI, Kim JH, Lee TY, Lee KW. Efficacy and safety of glaucoma patients’ switch from a 2% dorzolamide/0.5% timolol fixed-combination brand-name drug to its generic counterpart. J Ocul Pharmacol Ther. 2015;31(6):335–339. doi:10.1089/jop.2014.017026133057
- NetMBA. The product life cycle. NetMBA; 2010 Available from: http://www.netmba.com/marketing/product/lifecycle/. Accessed 830, 2016.
- Zhang J. AS. Market Analysis of Currently Available Prescription Drugs. Association for Business and Economics Research (ABER); 2009.
- H. B. Benefits and limitations of product life cycle; 2016 Available from: http://www.marketing91.com/benefits-and-limitations-of-product-life-cycle/. Accessed 531, 2018.